Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The primary endpoint in Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial published by Ridker et al 1 was non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. The authors concluded that canakinumab 150 mg reduced primary event rates compared with placebo (3.86 vs 4.11 per 100 person-years) with HR 0.85 (95%CI 0.74 to 0.98; P=0.021). Sample …
Contributors NG wrote the first draft of the letter. All three authors took the final decision and contributed in the final version.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.